{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:01:44Z","timestamp":1789750904164,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bmc.2025.118085","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T08:04:54Z","timestamp":1738137894000},"page":"118085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Novel dual-targeting PROTAC degraders of GSK-3\u03b2 and CDK5: A promising approach for pancreatic cancer treatment"],"prefix":"10.1016","volume":"120","author":[{"given":"Jayaprakash","family":"Neerasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongsu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunsuk","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118085_b0005","first-page":"1","article-title":"Current Therapeutic Targets in Cancer Cachexia: A Pathophysiologic Approach","volume":"43","author":"Kadakia","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.bmc.2025.118085_b0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118085_b0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118085_b0020","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118085_b0025","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.2147\/IJN.S413496","article-title":"Advances and prospects in the treatment of pancreatic cancer","volume":"18","author":"Duan","year":"2023","journal-title":"Int J Nanomed."},{"key":"10.1016\/j.bmc.2025.118085_b0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.bmc.2025.118085_b0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","article-title":"Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer","volume":"21","author":"Stoop","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bmc.2025.118085_b0040","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1074\/jbc.M116.764407","article-title":"CDK5\/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion","volume":"292","author":"Jin","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118085_b0045","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1158\/0008-5472.CAN-09-1107","article-title":"Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling","volume":"70","author":"Feldmann","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118085_b0050","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/biology10070610","article-title":"GSK-3\u03b2 in pancreatic cancer: spotlight on 9-ING-41, its therapeutic potential and immune modulatory properties","volume":"10","author":"Park","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.bmc.2025.118085_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.118626","article-title":"GSK-3: An important kinase in colon and pancreatic cancers","volume":"1867","author":"Vidri","year":"2020","journal-title":"Biochim Biophys Acta (BBA) \u2013 Mol Cell Res"},{"key":"10.1016\/j.bmc.2025.118085_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/930710","article-title":"GSK-3: A bifunctional role in cell death pathways","volume":"2012","author":"Jacobs","year":"2012","journal-title":"Int J Cell Biol"},{"key":"10.1016\/j.bmc.2025.118085_b0065","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1159\/000485580","article-title":"The key roles of GSK-3\u03b2 in regulating mitochondrial activity","volume":"44","author":"Yang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.bmc.2025.118085_b0070","doi-asserted-by":"crossref","first-page":"17373","DOI":"10.18632\/oncotarget.14538","article-title":"Biological functions of CDK5 and potential CDK5 targeted clinical treatments","volume":"8","author":"Shupp","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2025.118085_b0075","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.trecan.2016.09.001","article-title":"The emerging role of Cdk5 in cancer","volume":"2","author":"Pozo","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bmc.2025.118085_b0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-017-0611-1","article-title":"Cdk5 links with DNA damage response and cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2025.118085_b0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/14728222.2020.1743681","article-title":"Glycogen synthase kinase-3\u03b2: a novel therapeutic target for pancreatic cancer","volume":"24","author":"Ding","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bmc.2025.118085_b0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.MPA.0000335452.60538.7f","article-title":"CDK5 inhibition diminishes pancreatic cancer tumorigenesis and metastasis","volume":"37","author":"Feldmann","year":"2008","journal-title":"Pancreas"},{"key":"10.1016\/j.bmc.2025.118085_b0095","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1158\/1078-0432.CCR-10-2288","article-title":"Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-ras","volume":"17","author":"Eggers","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118085_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127375","article-title":"A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies","volume":"253","author":"Thapa","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.bmc.2025.118085_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100779","article-title":"GSK3\u03b2 as a novel promising target to overcome chemoresistance in pancreatic cancer","volume":"58","author":"Pecoraro","year":"2021","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bmc.2025.118085_b0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/156800907780618266","article-title":"Glycogen synthase kinase-3 beta; a new target in pancreatic cancer?","volume":"7","author":"Garcea","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.bmc.2025.118085_b0115","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3389\/fphar.2018.01525","article-title":"\u03b2-Sitosterol and gemcitabine exhibit synergistic anti-pancreatic cancer activity by modulating apoptosis and inhibiting epithelial\u2013mesenchymal transition by deactivating Akt\/GSK-3\u03b2 signaling","volume":"9","author":"Cao","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2025.118085_b0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11060-010-0491-3","article-title":"GSK-3\u03b2 inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line","volume":"104","author":"Dickey","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.bmc.2025.118085_b0125","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1021\/acschemneuro.0c00096","article-title":"Physiological and pathological roles of Cdk5: potential directions for therapeutic targeting in neurodegenerative disease","volume":"11","author":"Allnutt","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmc.2025.118085_b0130","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12943-023-01895-8","article-title":"CDK5: an oncogene or an anti-oncogene: location locationlocation","volume":"22","author":"Nikhil","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2025.118085_b0135","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.7150\/jca.14778","article-title":"Low expression of CDK5 and p27 Are associated with poor prognosis in patients with gastric cancer","volume":"7","author":"Sun","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.bmc.2025.118085_b0140","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational design of multitarget-directed ligands: strategies and emerging paradigms","volume":"62","author":"Junting","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118085_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216128","article-title":"PROTACs: novel tools for improving immunotherapy in cancer","volume":"560","author":"Li","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2025.118085_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28093698","article-title":"PROTACs in the management of prostate cancer","volume":"28","author":"Yedla","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118085_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108525","article-title":"Target protein degradation by protacs: a budding cancer treatment strategy","volume":"250","author":"Choudhary","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2025.118085_b0160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41589-021-00742-5","article-title":"Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy","volume":"17","author":"Wang","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2025.118085_b0165","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1021\/acs.jmedchem.4c00196","article-title":"Discovery of novel ER\u03b1 and aromatase dual-targeting PROTAC Degraders to overcome endocrine-resistant breast cancer","volume":"67","author":"Lilan","year":"2024","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmc.2025.118085_b0170","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1039\/C9CC00163H","article-title":"PROTACs suppression of CDK4\/6, crucial kinases for cell cycle regulation in cancer","volume":"55","author":"Zhao","year":"2019","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.bmc.2025.118085_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113849","article-title":"AZD5438-PROTAC: a selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss","volume":"226","author":"Hati","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118085_b0180","doi-asserted-by":"crossref","first-page":"14822","DOI":"10.1021\/acs.jmedchem.1c01350","article-title":"Discovery of potent and selective CDK9 degraders for targeting transcription regulation in triple-negative breast cancer","volume":"64","author":"Wei","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118085_b0185","doi-asserted-by":"crossref","first-page":"13865","DOI":"10.1002\/anie.202004087","article-title":"Development of CDK2 and CDK5 dual degrader TMX\u20102172","volume":"59","author":"Teng","year":"2020","journal-title":"Angew Chem"},{"key":"10.1016\/j.bmc.2025.118085_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113889","article-title":"Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer\u2019s disease","volume":"226","author":"Qu","year":"2021","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.bmc.2025.118085_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112949","article-title":"PROTACs suppression of GSK-3\u03b2, a crucial kinase in neurodegenerative diseases","volume":"210","author":"Jiang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118085_b0200","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1021\/acs.jmedchem.3c02332","article-title":"Beyond Rule of Five and PROTACs in modern drug discovery: polarity reducers, chameleonicity, and the evolving physicochemical landscape","volume":"67","author":"Price","year":"2024","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625000264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625000264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T21:29:09Z","timestamp":1740086949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625000264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":40,"alternative-id":["S0968089625000264"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118085","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel dual-targeting PROTAC degraders of GSK-3\u03b2 and CDK5: A promising approach for pancreatic cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118085"}}